Puma Biotechnology (PBYI) Non-Current Deffered Revenue (2011 - 2018)

Puma Biotechnology (PBYI) has 8 years of Non-Current Deffered Revenue data on file, last reported at $5.8 million in Q4 2018.

• Quarterly Non-Current Deffered Revenue rose 7.57% year-over-year to $5.8 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $5.8 million (up 7.57% YoY) and the FY2018 annual result came in at $5.8 million, up 7.57% from the prior year.
• Non-Current Deffered Revenue slipped to $5.8 million in Q4 2018, from $5.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $5.9 million in Q3 2018 to a low of $1.1 million in Q3 2014.
• A 5-year average of $3.6 million and a median of $5.1 million in 2016 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue declined 9.86% — and 2017, when it jumped 314.93%.
• Tracing PBYI's Non-Current Deffered Revenue over 5 years: stood at $1.3 million in 2014, then climbed by 9.77% to $1.4 million in 2015, then surged by 295.19% to $5.5 million in 2016, then declined by 1.8% to $5.4 million in 2017, then increased by 7.57% to $5.8 million in 2018.
• The last three Non-Current Deffered Revenue figures came in at $5.8 million (Q4 2018), $5.9 million (Q3 2018), and $5.5 million (Q2 2018), per Business Quant data.